Glaukos Corporation $GKOS Position Cut by WCM Investment Management LLC

WCM Investment Management LLC decreased its position in shares of Glaukos Corporation (NYSE:GKOS) by 4.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,427 shares of the medical instruments supplier’s stock after selling 3,940 shares during the quarter. WCM Investment Management LLC owned about 0.16% of Glaukos worth $9,811,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. First Horizon Corp increased its holdings in shares of Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Glaukos in the fourth quarter worth about $28,000. Larson Financial Group LLC grew its position in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares in the last quarter. Parallel Advisors LLC grew its position in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 215 shares during the period. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GKOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. JPMorgan Chase & Co. upped their price target on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Stifel Nicolaus raised their price objective on shares of Glaukos from $170.00 to $175.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright assumed coverage on shares of Glaukos in a research note on Monday, July 6th. They issued a “buy” rating and a $168.00 price objective on the stock. Finally, Wells Fargo & Company increased their target price on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.85.

Glaukos Trading Down 0.8%

Shares of GKOS opened at $155.54 on Tuesday. The business’s 50-day moving average price is $134.80 and its 200 day moving average price is $122.38. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $9.13 billion, a P/E ratio of -47.42 and a beta of 0.75. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.53.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.22) earnings per share. Analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current year.

Insider Activity

In related news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the transaction, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the sale, the chief operating officer directly owned 73,419 shares in the company, valued at approximately $10,538,563.26. This trade represents a 21.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,273 shares of company stock worth $8,882,003 in the last quarter. Insiders own 5.90% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.